HYDROXYZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H27ClN2O2
Molecular Weight	374.904
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCOCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=ZQDWXGKKHFNSQK-UHFFFAOYSA-N

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

HIDE SMILES / InChI

Molecular Formula	C21H27ClN2O2
Molecular Weight	374.904
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00557
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf

Hydroxyzine, a piperazine antihistamine structurally related to buclizine, cyclizine, and meclizine, is used to treat histamine-mediated pruritus or pruritus due to allergy, nausea and vomiting, and, in combination with an opiate agonist, anxiolytic pain. Hydroxyzine is also used as a perioperative sedative and anxiolytic and to manage acute alcohol withdrawal. Hydroxyzine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of hydroxyzine occur at the subcortical level of the CNS. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic. It is used for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Target ID: Leishmania (L.) infantum promastigotes viability Sources: https://www.ncbi.nlm.nih.gov/pubmed/24905294	Inhibitor 8228	59.57 µM [IC50]
Histamine H1 receptor 313 Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00557	Antagonist 2760
Monoamine oxidase B 72 Target ID: CHEMBL2993 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17447421	Inhibitor 8228	38.0 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 266 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf	Palliative		Approved 8360	VISTARIL Approved Use For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. Launch Date 7.8589441E11
Pruritus 29 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf	Palliative		Approved 8360	VISTARIL Approved Use For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. Launch Date 7.8589441E11

C_max

Value	Dose	Analyte	Population
31.371 ng/mL EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2313_001_PAR.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
72.5 ng/mL EXPERIMENT https://www.jacionline.org/article/0091-6749(84)90486-X/pdf	0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
72.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6141198/	0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
479.174 ng × h/mL EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2313_001_PAR.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROXYZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
18.4 h EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2313_001_PAR.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20 h EXPERIMENT https://www.jacionline.org/article/0091-6749(84)90486-X/pdf	0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6141198/	0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920	Disc. AE: Drowsiness... Other AEs: Drowsiness, Dry mouth... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Other AEs: Drowsiness (17 patients) Dry mouth (12 patients) Irritability (7 patients) Dizziness (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/365920

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920
Dry mouth	12 patients	50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920
Drowsiness	17 patients	50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920
Dizziness	3 patients	50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920
Irritability	7 patients	50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/365920	unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/365920

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
		inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Nav1.5 95 Cav1.2 45 P-gp 1437	P-gp 1527

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11290874/ Page: 5.0	likely
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/9616188/	yes [Ki 4 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12584158/ Page: 6.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Cav1.2 49	inhibitor 1613 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415947/
Nav1.5 98	inhibitor 1613 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415947/
hERG 1632	inhibitor 1613 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415947/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5818	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5818
ChemicalBook	CB2547530	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2547530
MolPort	MolPort-002-506-318	https://www.molport.com/shop/molecule-link/MolPort-002-506-318
eMolecules	1987151	https://www.emolecules.com/cgi-bin/more?vid=1987151

PubMed

Title	Date	PubMed
Peripheral antihistamine and central sedative effects of three H1-receptor antagonists.	1985	2864258
A comparison of acrivastine versus hydroxyzine and placebo in the treatment of chronic idiopathic urticaria.	1989	2569996
Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine.	1989 Sep	2570798
Controlled trial of H1 antagonists in the treatment of chronic idiopathic urticaria.	1991 Oct	1683191
Prolonged penile erections induced by hydroxyzine: possible mechanism of action.	1994	7969858
Hydroxyzine inhibits neurogenic bladder mast cell activation.	1998 Oct	9839659
Cetirizine-induce cholestasis.	2000 Oct	11034010
Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194).	2002 Feb	11809864
[Pruritus without skin manifestation--what kind of state of the art nursing intervention?].	2003 Oct	14619217
P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.	2003 Oct	14502547
Case studies: Use of salicylic acid (Avosil) and hydrogel (Avogel) in limiting scar formation.	2005 Mar 28	16921411
Free radical oxidation in rat brain during chronic stress and pharmacological regulation of this process.	2005 Oct	16671569
[The use of atarax in the treatment of tic hyperkinesia in children: a pilot study].	2006	17117677
[Use of anxiolytic atarax as a substitutive drug for benzodiazepine tranquilizers].	2007	18379511
Depressive symptoms in urticaria patients treated with first- or second-generation histamine 1 receptor antagonists.	2007 Aug	17632232
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.	2009	19549290
Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H.	2010	19672097
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses. As a sedative when used as a premedication and following general anesthesia: 50-100 mg in adults, and 0.6 mg/kg in children.

Route of Administration: Oral

In Vitro Use Guide

Hydroxyzine reduced carbachol-induced serotonin release by 25% at 10(-6) M and 34% at 10(-5) M in rat bladder mast cells

Substance Class	Chemical Created by `admin` on `Thu Jul 06 00:34:59 UTC 2023` Edited by `admin` on `Thu Jul 06 00:34:59 UTC 2023`
Record UNII	30S50YM8OG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROXYZINE

Official Name

English

(±)-2-(2-(4-(P-CHLORO-.ALPHA.-PHENYLBENZYL)-1-PIPERAZINYL)ETHOXY)ETHANOL

Common Name

English

MAREX

Brand Name

English

U.C.B-4492

Brand Name

English

HYDROXYZINE [MI]

Common Name

English

ETHANOL, 2-(2-(4-(4-CHLORO-.ALPHA.-PHENYLBENZYL)-1-PIPERAZINYL)ETHOXY)-

Systematic Name

English

(±)-HYDROXYZINE

Common Name

English

HYDROXYZINE [MART.]

Common Name

English

HYDROXYZINE [VANDF]

Common Name

English

ETHANOL, 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPERAZINYL)ETHOXY)-

Systematic Name

English

2-(2-(4-(P-CHLORO-.ALPHA.-PHENYLBENZYL)-1-PIPERAZINYL)ETHOXY)ETHANOL

Common Name

English

HYDROXYZINE [HSDB]

Common Name

English

ETHANOL, 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPERAZINYL)ETHOXY)-,(±)-

Common Name

English

TRANQUIZINE

Brand Name

English

Hydroxyzine [WHO-DD]

Common Name

English

1-(P-CHLORO-.ALPHA.-PHENYLBENZYL)-4-(2-((2-HYDROXYETHOXY)ETHYL))PIPERAZINE

Common Name

English

1-(P-CHLOROBENZHYDRYL)-4-(2-(2-HYDROXYETHOXY)ETHYL)DIETHYLENEDIAMINE

Common Name

English

ATARAXOID

Brand Name

English

2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPERAZINYL)ETHOXY)ETHANOL

Systematic Name

English

NSC-169188

Code

English

hydroxyzine [INN]

Common Name

English

TRAN-Q

Brand Name

English

Classification Tree Code System Code

LIVERTOX

NBK548128

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

NDF-RT

N0000175750

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

NDF-RT

N0000000207

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

WHO-VATC

QN05BB01

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

NCI_THESAURUS

C29578

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

WHO-ATC

N05BB01

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

WHO-VATC

QN05BB51

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

WHO-ATC

N05BB51

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

Code System Code Type Description

NSC

169188

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

LACTMED

Hydroxyzine

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

PUBCHEM

3658

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

NCI_THESAURUS

C29103

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

RXCUI

5553

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

RxNorm

FDA UNII

30S50YM8OG

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

HSDB

3098

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

EPA CompTox

DTXSID8023137

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

SMS_ID

100000083664

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

CAS

147152-21-4

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

SUPERSEDED

MERCK INDEX

M6159

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

Merck Index

INN

599

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

WIKIPEDIA

HYDROXYZINE

Created by admin on Thu Jul 06 00:35:00 UTC 2023 , Edited by admin on Thu Jul 06 00:35:00 UTC 2023

PRIMARY

ECHA (EC/EINECS)

200-693-1

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

IUPHAR

7199

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

CHEBI

5818

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

MESH

D006919

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

DRUG CENTRAL

1400

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

DAILYMED

30S50YM8OG

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

DRUG BANK

DB00557

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

ChEMBL

CHEMBL896

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

EVMPD

SUB08088MIG

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

CAS

68-88-2

Created by admin on Thu Jul 06 00:34:59 UTC 2023 , Edited by admin on Thu Jul 06 00:34:59 UTC 2023

PRIMARY

Related Record Type Details


					76755771U3

HYDROXYZINE DIHYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Amount:


					M20215MUFR

HYDROXYZINE PAMOATE

SALT/SOLVATE -> PARENT

Amount:


					CA67JF5Q4W

HYDROXYZINE MONOHYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Amount:


					28XBT591QG

HISTAMINE H1 RECEPTOR

TARGET -> INHIBITOR

Amount:


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> INHIBITOR

Comments:

Inhibition of bufuralol 1′-hydroxylation. Could be clinically relevant concentration in liver is within these values.

Interaction Type:

COMPETITIVE INHIBITOR

Qualification:

Ki

Amount:


					SEV29N8JND

POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY H MEMBER 2

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					YO7261ME24

CETIRIZINE

METABOLITE ACTIVE -> PARENT

Amount:


					V5V8VYQ65X

4-CHLOROBENZHYDROL

METABOLITE INACTIVE -> PARENT

Amount:

Related Record Type Details


					30S50YM8OG

HYDROXYZINE

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

PLASMA CONCENTRATION	PHARMACOKINETIC
LIVER/PLASMA RATIO	PHARMACOKINETIC

LIVER CONCENTRATION	PHARMACOKINETIC

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00557Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00557
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf

C_max

T_1/2

Drug as perpetrator